Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Forsteo ® (teriparatid)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Forsteo is contraindicated in patients with prior external beam or implant radiation therapy to the skeleton.1
Forsteo should not be prescribed for patients who are at an increased baseline risk for osteosarcoma.2
Radiation-induced osteosarcoma is a rare, but well-recognized, complication in human radiotherapy patients. Patients who have had prior radiation therapy have an increased risk of developing a radiogenic second malignant neoplasm, including osteosarcoma, some years or decades after initial treatment.3,4
If a patient is receiving teriparatide and develops a need for radiation therapy, Lilly advises that the teriparatide treatment be discontinued immediately or prior to radiation therapy.
1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3. Kalra S, Grimer RJ, Spooner D, et al. Radiation-induced sarcomas of bone: factors that affect outcome. J Bone Joint Surg Br. 2007;89-B(6):808-813. http://dx.doi.org/10.1302/0301-620X.89B6.18729
4. Newhauser WD, Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer. 2011;11(6):438-448. http://dx.doi.org/10.1038/nrc3069
Datum fӧr senaste ӧversyn 2020 M02 05